l e t t e r S In adipose tissue, muscle, liver and macrophages, signaling by the nuclear receptor peroxisome proliferator-activated receptor-g (PPAR-g) is a determinant of insulin sensitivity and this receptor mediates the insulin-sensitizing effects of thiazolidinediones (TZDs) [1] [2] [3] [4] . As PPAR-g is also expressed in neurons 5 , we generated mice with neuron-specific Pparg knockout (Pparg brain knockout (BKO)) to determine whether neuronal PPAR-g signaling contributes to either weight gain or insulin sensitivity. During high-fat diet (HFD) feeding, food intake was reduced and energy expenditure increased in Pparg-BKO mice compared to Pparg f/f mice, resulting in reduced weight gain. Pparg-BKO mice also responded better to leptin administration than Pparg f/f mice. When treated with the TZD rosiglitazone, Pparg-BKO mice were resistant to rosiglitazone-induced hyperphagia and weight gain and, relative to rosiglitazone-treated Pparg f/f mice, experienced only a marginal improvement in glucose metabolism. Hyperinsulinemic euglycemic clamp studies showed that the increase in hepatic insulin sensitivity induced by rosiglitazone treatment during HFD feeding was completely abolished in Pparg-BKO mice, an effect associated with the failure of rosiglitazone to improve liver insulin receptor signal transduction. We conclude that excess weight gain induced by HFD feeding depends in part on the effect of neuronal PPAR-g signaling to limit thermogenesis and increase food intake. Neuronal PPAR-g signaling is also required for the hepatic insulin sensitizing effects of TZDs.
TZDs are a class of drugs that activate PPAR-g and improve blood glucose control and systemic insulin sensitivity in patients with type 2 diabetes mellitus (T2DM) 6 . In addition to enhancing insulin action, TZDs induce weight gain in humans and rodent models not only via enhanced adipogenesis and fluid retention but also by increasing food intake 7, 8 . This latter effect suggests that PPAR-g signaling in the central nervous system (CNS) may influence energy intake and storage. Consistent with this hypothesis, PPAR-g is expressed in key brain areas involved in energy homeostasis and glucose metabolism 5 , raising the possibility that the CNS might be a previously unrecognized site for TZD action.
To investigate the function of neuronal PPAR-g, we generated Pparg-BKO mice using the synapsin I Cre-LoxP system. Cre expression driven by the synapsin I promoter (Syn1-Cre) leads to recombination in neurons, but not other cell types 9 . To verify brain-specific deletion of Pparg in Pparg-BKO mice, we isolated RNA from multiple brain regions and from peripheral tissues for measurement of Pparg mRNA abundance. Quantitative PCR (qPCR) showed that brain Pparg deletion was regional, with markedly reduced mRNA abundance in spinal cord, brain stem, hypothalamus, diencephalon and hippocampus, mildly reduced expression in cerebral cortex and unchanged levels in cerebellum and olfactory bulb, compared to mice carrying Pparg floxed alleles (Pparg f/f mice) ( Fig. 1a) . We further confirmed neuronspecific deletion in the Pparg-BKO mice by double staining for PPAR-g and the neuronal marker NeuN, and found that PPAR-g is expressed in both neurons and non-neuronal cells in the CNS, albeit with distinctive patterns in different regions. In the hippocampus, for example, most PPAR-g + cells were also NeuN + and, accordingly, the number of double positive cells was reduced in Pparg-BKO mice ( Supplementary  Fig. 1 ). In contrast, the majority of PPAR-g + cells in the cortex were NeuN − , indicating non-neuronal PPAR-g expression ( Supplementary  Fig. 1 ). These histochemical data are fully consistent with the qPCR analysis, showing a much greater reduction of Pparg mRNA in the hippocampus than in cortex of Pparg-BKO mice.
PCR detection of the smaller band with deletions of exons 3 and 4 in genomic DNA (data not shown) and mRNA ( Fig. 1b ) from various tissues of Pparg-BKO mice showed Cre-mediated recombination in brain, but not in muscle, liver, adipose tissue, pancreas or other tissues. We also confirmed that in Pparg-BKO mice, tissues other than brain showed normal Pparg expression ( Fig. 1c) .
Body weights of Pparg-BKO mice fed a standard chow diet were slightly, but significantly (P < 0.05), lower than Pparg f/f mice at a young age (8-11 weeks), but these differences were transient, disappearing by 13 weeks (Supplementary Fig. 2a ). Metabolic studies on standard chow-fed mice did not reveal any difference between genotypes ( Supplementary Fig. 2b-f ).
When we placed 12-week-old Pparg f/f and Pparg-BKO mice on a HFD, the body weight curves diverged over a 7-week period, with reduced weight gain in Pparg-BKO mice ( Fig. 2a) . Body composition analysis revealed that this weight difference was due to a reduced body fat percentage in Pparg-BKO mice compared to Pparg f/f mice fed the same HFD ( Fig. 2b) . To determine whether differences in energy intake, energy expenditure or both contribute to the lean phenotype of Pparg-BKO mice, we measured food intake and metabolic parameters during HFD feeding. Ambulatory activity and oxygen consumption were increased in Pparg-BKO mice, compared to Pparg f/f mice, in both dark and light cycles ( Fig. 2c) . Multiple regression analysis 10 showed increased energy expenditure in Pparg-BKO mice after adjusting for differences of body weight, composition and physical activity ( Fig. 2d and Supplementary Table 1 ). As Pparg-BKO mice also consumed less food over the course of 12 weeks of HFD feeding ( Fig. 2e ) than Pparg f/f mice, their protection against HFD-induced obesity involves both increased energy expenditure and reduced energy intake, indicating that neuronal PPAR-g signaling is required for the effects of HFD feeding on both sides of the energy balance equation.
Leptin is an adipokine that increases energy expenditure and reduces energy consumption via central effects 11 , and the effects of HFD feeding to reduce leptin sensitivity are well established 12 . As Pparg-BKO mice are protected against excess weight gain on this diet, we hypothesized that neuronal PPAR-g signaling contributes to leptin resistance in PPAR-g replete mice on HFD. Although the basal circulating leptin concentration was comparable between Pparg f/f mice and Pparg-BKO mice ( Fig. 2f) , leptin sensitivity was increased in Pparg-BKO mice when measured as a function of the effect on food intake by leptin administration for 48 h. Leptin induced a larger decrease of food intake in Pparg-BKO mice fed standard chow compared to either Pparg f/f mice or Syn1-Cre mice ( Supplementary Fig. 3a ), despite no differences in body weight among these three groups (data not shown). We observed a similar, but statistically insignificant (P = 0.14), trend in HFD-fed Pparg-BKO mice ( Supplementary Fig. 3b ). Thus, neuronal Pparg deficiency seems to sensitize mice to leptin's anorexigenic effects. l e t t e r S To assess leptin responsiveness by a biochemical approach, we measured phosphorylation of signal transducer and activator of transctiption-3 (STAT3), a downstream mediator of intracellular leptin signaling, in hypothalamic extracts after a single intraperitoneal leptin injection. As expected, HFD feeding caused leptin resistance in Pparg f/f mice, as indicated by the failure of leptin to increase hypothalamic phospho-STAT3 (on Tyr705) abundance 12 . In contrast, hypothalamic phospho-STAT3 amounts were higher in leptin-treated relative to vehicle-treated Pparg-BKO mice (Fig. 2g) .
To determine whether neuronal PPAR-g signaling contribute to the actions of TZDs, we fed mice a HFD to induce obesity and insulin resistance, followed by a HFD supplemented with rosiglitazone. As expected, the addition of rosiglitazone led to an increase of body weight and food intake in both Pparg f/f mice and Syn1-Cre mice compared to age-matched mice fed the same diet without rosiglitazone for the same period of time (28-34 weeks of age) ( Fig. 3a-c) . Relative to Pparg f/f mice, the effects of rosiglitazone to increase food intake and body weight in Pparg-BKO mice were attenuated by ~50% (change in body weight in Pparg f/f versus Pparg-BKO mice = 4.7 g versus 2.2 g; Fig. 3a-c) . To further characterize this aspect of the Pparg-BKO phenotype, we initiated HFD and rosiglitazone treatment simultaneously in standard chow-fed mice. As expected, the resulting weight gain over the subsequent 2-week period was substantially smaller in Pparg-BKO mice than in Pparg f/f mice (Supplementary Fig. 3c ). Thus, neuronal PPAR-g is required, at least in part, for TZD-induced hyperphagia and weight gain.
The increased energy expenditure observed in Pparg-BKO mice prompted us to assess the expression of thermogenic genes in brown and white adipose tissue. Consistent with previous publications 13 , rosiglitazone administration to Pparg f/f mice increased expression of Ucp1 (encoding uncoupling protein-1) mRNA in white adipose tissue (WAT) and Ucp3 mRNA in liver and muscle ( Fig. 3d-h) .
Notably, Ucp1 mRNA expression in WAT of Pparg-BKO mice was higher than control values before rosiglitazone treatment, and rosiglitazone treatment enhanced WAT Ucp1 mRNA expression in Pparg-BKO mice to a greater extent than in Pparg f/f mice (Fig. 3d) . Thus, the effect of rosiglitazone to increase WAT Ucp1 expression is enhanced in mice with neuron-specific Pparg deletion. Ucp1 mRNA content in brown adipose tissue (BAT) was also elevated in Pparg-BKO mice (Fig. 3e) , and this effect was associated with decreased BAT lipid accumulation (Fig. 3f) . In muscle, Ucp3 mRNA expression was similar between genotypes both before and after rosiglitazone treatment (Fig. 3g) , whereas in liver rosiglitazone induction of Ucp3 expression was markedly augmented in Pparg-BKO mice (Fig. 3h) . These observations collectively identify mitochondrial uncoupling in WAT and other tissues as a probable mechanism for the increased energy expenditure in mice with neuronal Pparg deficiency. By extension, we infer a physiological role for neuronal PPAR-g signaling to limit expression of UCPs in adipose tissue and liver and thereby limit energy expenditure.
As increased mitochondrial uncoupling in adipose tissue can result from increased thyroid hormone signaling, we assessed the thyroid axis in Pparg-BKO mice. We found that these mice show normal plasma thyroid hormone concentrations (Supplementary Fig. 3d,e ) and normal hypothalamic expression of both thyroid hormone receptor and thyrotropin-releasing hormone ( Supplementary  Fig. 3f ). Thus, altered thyroid function is an unlikely contributor to the hypermetabolic phenotype of these mice. Similarly, measures of blood pressure, heart rate and catecholamine concentrations were the same between genotypes (Supplementary Fig. 4a-c) , indicating that stress is not the mechanism driving the hypermetabolic phenotype of Pparg-BKO mice.
We next evaluated the contribution of neuronal PPAR-g to the control of insulin sensitivity in both the presence and absence of rosiglitazone. After either 3 or 7 weeks of rosiglitazone treatment, glucose tolerance was markedly improved in HFD-fed Pparg f/f mice, but not in Pparg-BKO mice, despite equally reduced fasting free fatty acid concentrations ( Fig. 4a and Supplementary Fig. 4d,e ). Hyperinsulinemic-euglycemic clamp measurements provide a quantitative assessment of insulin sensitivity in vivo and, as expected, we found that in Pparg f/f mice rosiglitazone treatment significantly increased both the glucose infusion rate (GIR, a measure of wholebody insulin action) and the insulin-stimulated glucose disposal rate (IS-GDR) (Fig. 4b,c) . At the same time, drug treatment lowered basal hepatic glucose production (HGP) while enhancing the ability of insulin to inhibit HGP (Fig. 4d,e) .
Compared to Pparg f/f mice, Pparg-BKO mice were less insulin sensitive after rosiglitazone treatment. Notably, the beneficial effects of rosiglitazone on both basal HGP and insulin-induced suppression of HGP were completely abolished in the Pparg-BKO mice (Fig. 4d-f) , despite the fact that these mice consumed less food and gained less weight (Fig. 3b,c) . Although GIR and IS-GDR values were moderately reduced in rosiglitazone-treated Pparg-BKO mice, the incremental values for IS-GDR between the untreated and treated state were comparable (13 versus 11 mg per kg body weight per min) between genotypes.
Supporting the functional readouts from the clamp studies, biochemical measures of hepatic insulin signaling were also blunted in rosiglitazone-treated Pparg-BKO mice relative to Pparg f/f mice, as reflected by decreased AKT kinase and glycogen synthase kinase-3 phosphorylation after acute insulin stimulation (Fig. 4g,h) . Rosiglitazone-treated Pparg-BKO mice also exhibited increased hepatic cAMP response element-binding protein phosphorylation and elevated phosphoenolpyruvate carboxykinase expression ( Fig. 4g,i) , whereas Socs3 (encoding suppressor of cytokine signaling-3) mRNA content was higher in rosiglitazone-treated Pparg-BKO mice compared to Pparg f/f mice (Supplementary Fig. 5a) . As SOCS3 is a negative regulator of insulin signaling, this latter effect could potentially contribute to liver insulin resistance in these mice during TZD treatment. Finally, liver diacylglycerol and ceramide concentrations were lowered by rosiglitazone treatment in both genotypes (Supplementary Table 2) , but rosiglitazone treatment increased liver weight only in Pparg f/f mice, not in Pparg-BKO mice (Fig. 4j) .
Tissue inflammatory gene expression did not differ between genotypes ( Supplementary Fig. 5b-d) , nor were circulating cytokine or adiponectin concentrations different between Pparg-BKO mice and Pparg f/f mice (Supplementary Fig. 6 ). Thus, neither increased systemic inflammation nor differences in adiponectin levels can explain the relative insulin resistance of rosiglitazone-treated Pparg-BKO mice.
Our results show unexpected effects of brain PPAR-g on food intake, energy expenditure and insulin sensitivity. Deletion of brain Pparg led to both reduced food intake and increased energy expenditure, effects l e t t e r S that were specific to consumption of a HFD and that protected mice from excess weight gain and adiposity in this setting. One potential mechanism to explain this outcome is increased central leptin sensitivity and associated increases of Ucp1 expression in BAT and WAT and Ucp3 expression in liver of Pparg-BKO mice. With respect to our biochemical leptin sensitivity assays, the basic phenotype of the Pparg-BKO mice is that they weigh less than Pparg f/f mice, so their increased biochemical leptin sensitivity could have been secondary to their protection against obesity rather than a direct consequence of neuronal Pparg deficiency. Although future studies are warranted to address this issue, in either case the data collectively indicate that the phenotype of Pparg-BKO mice includes increased leptin sensitivity.
We also observed protection against rosiglitazone-induced hyperphagia and weight gain in Pparg-BKO mice. However, despite their reduced adiposity, these mice had impaired glucose tolerance and reduced insulin sensitivity during rosiglitazone treatment, compared to Pparg f/f mice. Of particular relevance is the liver-specific nature of the impaired response to rosiglitazone in these mice, which implies that the effect of rosiglitazone to improve insulin sensitivity in liver, but not in other tissues, involves a CNS mechanism. We conclude that neuronal PPAR-g contributes to excess weight gain during HFD feeding and in response to rosiglitazone treatment and is also required for the rosiglitazone-mediated improvement of liver insulin sensitivity. These studies define a new role for brain PPAR-g as both an integrator of signals affecting energy balance and glucose homeostasis and as a target for the action of TZDs.
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ONLINe MeTHODs
Mice. We backcrossed Pparg f/f mice 1 onto C57BL/6 background for more than ten generations. We backcrossed transgenic mice Syn1-Cre mice 9 onto the C57BL/6 background for more than six generations. We bred Pparg f/f mice with Syn1-Cre mice to generate Pparg f/+ mice with a positive Cre gene, which we further bred with Pparg f/f mice to obtain Pparg-BKO mice. Because male mice carrying Syn1-Cre can occasionally generate germline deletion of the target gene in progeny due to expression of Cre recombinase in sperm 14 , we screened all Pparg-BKO mice for germline deletion (for example, heterozygous whole-body Pparg-knockout mice) and eliminated such mice from our studies. We used only male mice for experiments. We housed mice in a 12-h light, 12-h dark cycle. At 12 weeks of age, mice were either fed normal chow diet (LabDiet) or 60% HFD (Research Diets). At week 16 on HFD, a subset of mice was switched to 60% HFD with rosiglitazone (3 mg per kg body weight per day) for up to 10 weeks.
Mouse procedures conformed to the Guide for Care and Use of Laboratory Animals of the US National Institutes of Health and were approved by the Animal Subjects Committee of UCSD.
Metabolic studies. We performed hyperinsulinemic euglycemic clamp studies as previously described 15 . We only used mice that lost <6% of their precannulation weight after 4-5 d of recovery. The clamp experiments began with a constant infusion (5 µCi h −1 ) of D-[3-3H] glucose (Du Pont-NEN) in 6-h-fasted mice. After 90 min of tracer equilibration and basal sampling, we infused glucose (50% dextrose; Abbott) and tracer (5 µCi h −1 ) plus insulin (6 mU kg −1 min −1 ) into the jugular vein. We drew small blood samples from the tail vein at 10-min intervals and confirmed the achievement of steady-state conditions (120 mg dl −1 ± 5 mg dl −1 ) at the end of the clamp by maintaining glucose infusion and plasma glucose concentration for a minimum of 20 min. We took blood samples at t = −10, 0 (basal), 110 and 120 (end of experiment) min to determine glucose-specific activity and insulin concentration. We quantified tracer-determined rates by using the Steele equation for steadystate conditions 16 . At steady state, the rate of glucose disappearance, or total GDR, is equal to the sum of the rate of endogenous glucose productions (HGP) plus the exogenous (cold) GIR. The IS-GDR is equal to the total GDR minus the basal glucose turnover rate. We performed other metabolic measurements as previously described 15, 17, 18 .
For assay of biochemical responses to insulin stimulation, we anesthetized mice after a 6-h fast. We ligated vessels supplying one side of leg muscles, one lobe of the liver and one epididymal fat pad and took basal samples of liver, muscle and fat. Five minutes after a bolus injection of insulin (1 U kg −1 via inferior vena cava), we collected the remaining liver, muscle and fat and snap froze to measure signal transduction markers.
Body composition, locomotor activity and indirect calorimetry.
We measured mouse lean and fat mass by quantitative magnetic resonance spectroscopy (Echo Medical Systems) after 5 weeks of HFD. At week 6 of HFD, we individually placed mice into metabolic cages for measurements. We adapted all mice to the new environment for 48 h before study. We normalized oxygen consumption (VO 2 ) and carbon dioxide production (VCO 2 ) by a multiple regression-based approach 10 to account for variation of both lean and fat mass. We calculated energy expenditure on the basis of the formula energy expenditure = 3.815 × VO 2 + 1.232 × VCO 2 .
Biochemical leptin sensitivity assays. After 8 weeks of HFD feeding, we injected overnight-fasted Pparg f/f and Pparg-BKO mice intraperitoneally with either vehicle (10 mM NaHCO 3 , pH 7.9) or recombinant mouse leptin at 1 mg per kg body weight (National Institute of Diabetes and Digestive and Kidney Diseases and The National Hormone and Pituitary Program) and decapitated mice 90 min later. We rapidly dissected and froze the hypothalami for detection of phosphoSTAT3 (Tyr705) and STAT3 by immunoblotting.
Western blotting. We performed western blotting as previously described 19 . We purchased all primary antibodies, except antibody to β-tubulin (Millipore), from Cell Signaling Technology . We analyzed the protein bands with Image J densitometry analysis and normalized phosphorylated protein abundance to total protein bands.
Gene expression analyses.
We carried out qPCR as previously described 15 . We measured mRNA of Pparg using the following primer set: 5′-GTCACGTT CTGACAGGACTGTGTGAC-3′ and 5′-GGGTCAGCTCTTGTGAATGGAA TG-3′, in which the reverse primer detects the exon absent in the mutant mice. We normalized the mRNA content of all genes reported to housekeeping genes (encoding cyclophilin A and RNA polymerase II). For detection of mutant Pparg mRNA, we used the following primer set that binds to sequences flanking the absent exons: 5′-GTCACGTTCTGACAGGACTGTGTGAC-3′ and 5′-TATCACTGGAGATCTCCGCCAACAGC-3′.
